Laird Norton Wetherby Wealth Management LLC Purchases 158,143 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

Laird Norton Wetherby Wealth Management LLC increased its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 376.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 200,098 shares of the company's stock after purchasing an additional 158,143 shares during the period. Laird Norton Wetherby Wealth Management LLC's holdings in Dr. Reddy's Laboratories were worth $3,160,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its holdings in shares of Dr. Reddy's Laboratories by 423.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock valued at $29,000 after purchasing an additional 1,507 shares during the last quarter. Glass Jacobson Investment Advisors llc raised its holdings in shares of Dr. Reddy's Laboratories by 400.0% during the fourth quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company's stock valued at $32,000 after purchasing an additional 1,600 shares during the last quarter. POM Investment Strategies LLC increased its holdings in Dr. Reddy's Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after buying an additional 1,820 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in Dr. Reddy's Laboratories by 461.0% during the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock valued at $40,000 after buying an additional 2,093 shares during the last quarter. Finally, Sierra Ocean LLC purchased a new stake in Dr. Reddy's Laboratories during the fourth quarter valued at approximately $43,000. 3.85% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a report on Thursday, May 8th.

Dr. Reddy's Laboratories Stock Performance

RDY stock traded up $0.05 during midday trading on Friday, reaching $14.44. 1,085,237 shares of the company's stock traded hands, compared to its average volume of 1,491,451. Dr. Reddy's Laboratories Limited has a 52-week low of $12.26 and a 52-week high of $16.89. The stock has a market cap of $12.05 billion, a P/E ratio of 22.99 and a beta of 0.33. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The stock's 50-day moving average is $13.43 and its 200 day moving average is $14.03.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported $0.22 EPS for the quarter, beating analysts' consensus estimates of $0.20 by $0.02. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The business had revenue of $996.17 million during the quarter, compared to analysts' expectations of $83.70 billion. As a group, analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.